title: [Traceability of drugs derived from blood: regulation and pharmaco-economic implications after 24 months of application in Paris CHU].
abstract: Since January 1, 1995, the supply, stockage, dispensing and traceability of Blood Derivative Medicinal Products (BDMP) are subject to pharmaceutical regulations. A review of 24 months' application at Necker-Enfants Malades Hospital is presented and analysed. A distinction is drawn between two categories of BDMP: 1) anti-hemophilia BDMP, factors of plasma or recombinant origin; 2) non-anti-hemophilia BDMP, covering albumin, immunoglobulins (Ig), biological glues and other clotting factors. BDMP are subject to a hospital traceability procedure. In this respect, we have constructed a tryptic nominative model prescription, though dotations are granted for only certain prescription sectors (operating room, ICU) and certain products (biological glues, albumins). A dispensing-administration form is invariably attached to each bottle. Between January 1, 1995 and December 31, 1996, 8225 dispensing procedures for BDMP were recorded, with a total cost of 52,931,586 francs (i.e. 69% anti-hemophilia products v.s. 31% non-antihemophilia products). The Factor VIII market is divided more or less equally between factors of human and recombinant origin. The risk of viral transmission is considered to be virtually nil with recombinant products, despite their being stabilized by human albumin. The traceability rate of anti-hemophilia factors was 100%. Albumin consumption was 182,106 g at a cost of 3,358,250 francs. The following indications were adopted at a Local Medicines Committee: 1) in adults: hypoalbuminemia associated with edema or ascites; 2) in children: digestive disorders leading secondarily to exsudative enteropathy and/or hypoalbuminemia. Consumption of polyvalent Ig was 69,213 g, i.e. 10,856,722 francs. These products were prescribed in accordance with the directives of the Committee for Evaluation and Distribution of Technological Innovations. Consumption of specific Ig and biological glues may seem modest in relation to that of other products. BDMP expenditure appears particularly heavy here (about 26.5 MF/year) but consensual adoption of therapeutic guidelines has enabled rationalization of prescribing conditions with the best possible consideration of benefit/risk vs costs ratios. Traceability and drug safety monitoring procedures are linked to and integrated in the more global concept of Quality Assurance. Since January 1995, several withdrawals of batches have been recorded because of suspicion (or death due to) Creutzfeld-Jakob, or post-donation HIV seroconversion. In this area, the Hospital Pharmacist acts by the establishment in real time of a permanent safety link between the patient, a prescriber, an indication, a product prescribed and the product actually administered.
authors.affiliation: Service de Pharmacie Clinique, G.H. Necker-Enfants Malades, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Lesne-Hulin
authors.forename: P
authors.initials: P
authors.lastname: Bourget
authors.forename: M
authors.initials: M
authors.lastname: Silvie
authors.forename: V
authors.initials: V
authors.lastname: Barath
authors.forename: E
authors.initials: E
authors.lastname: Singlas
mesh_terms: D000328:Adult; D001779:Blood Coagulation Factors / Q000191:economics / Q000627:therapeutic use; D001798:Blood Proteins / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D016358:Contact Tracing; D011307:Drug Prescriptions / Q000191:economics; D017850:Economics, Pharmaceutical; D015658:HIV Infections / Q000635:transmission; D006467:Hemophilia A / Q000188:drug therapy; D006785:Hospitals, University / Q000191:economics; D006801:Humans; D007116:Immunization, Passive / Q000191:economics; D010297:Paris; D011785:Quality Assurance, Health Care; D012709:Serum Albumin / Q000191:economics / Q000627:therapeutic use
chemical_list: D001779:Blood Coagulation Factors; D001798:Blood Proteins; D012709:Serum Albumin
vernacular_title: Traçabilité des médicaments dérivés du sang: réglementation et implications pharmaco-économiques après 24 mois d'exercice dans un CHU Parisien.